A PROSPECTIVE, MULTICENTRE, POST-MARKETING PHASE IV STUDY TO ASSESS THE SAFETY AND EFFICACY OF LENVATINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous on Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer after Progression on Osimertinib and Chemotherapy
A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated participants with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer (NSCLC).
A Prospective, Randomized, Multicenter, Comparative, Double-blind, Parallel study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) with Reference Pertuzumab (Perjeta®, Genentech Inc.,) in Previously Untreated Patients with HER2 Positive Metastatic Breast Cancer.
A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Durvalumab Monotherapy in Participants with MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC) (SAMETA)
A multicenter, open label, randomized, phase III clinical trial to evaluate efficacy & safety of PF 114 versus imatinib at 600 or 800 mg daily in adult patients with Philadelphia chromosome positive (Ph positive) chronic myeloid leukemia (CML) in the chronic phase (CP) resistant to imatinib at daily doses of 400 or 600 mg
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non-Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD-(L)1 Therapy And Platinum Based Chemotherapy
A Randomized, Double-Blind Clinical Study of the Efficacy and Safety of BCD-201 (JSC BIOCAD) and Keytruda® in Patients with Unresectable or Metastatic Melanoma
A Prospective, Open label, Single arm, Multi-centric, Investigator initiated study (IIS) for evaluation of efficacy and safety of Levonadifloxacin (IV And Oral) for Gram-Positive Bacterial Infection in Immunocompromised patients.
Gynecology Department
A Multicentre, Randomized, Double Blind, Placebo-Controlled, Parallel Arm Study of the Effect of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignan Ascites.
A Randomized Open-Label, Multicentre, Phase 3 study of Epoetin Alfa Plus Standard Supportive Care versus Standard Supportive Care In Anemic Patients with Metastatic Breast Cancer Receiving First-Line Standard Chemotherapy. Protocol No. EPO-ANE-3010 (Johnson & Johnson)
Other Hospital approval under Somani hospital ethics committee
A Phase 3 Randomized, Double-Blind, parallel Group, Multicenter study to compare Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BP05 Versus EU-Approved Lucentis® in Patients with Wet (Neovascular) Age-Related Macular Degeneration. (Eye trial)
A Phase 3, Multicenter, prospective, Randomized, Double-Masked, Parallel-Group study of EYP-1901, a Tyrosine Kinase inhibitor (TKI), compared to aflibercept in subjects with Wet AMD. (Eye trial)
A Phase III, Double masked randomized multicenter study of the efficacy and safety of OCS-01 Eye drop in subjects with diabetic macular edema. (Eye trial)
A prospective, observational, multicenter Real-World Evidence study to assess the effectiveness & safety of CIDMUS (sacubitril - valsartan) in Heart Failure with reduced Ejection Fraction (HFrEF) and Heart Failure with mid-range ejection fraction (HFmrEF) patients in India. (cardiology trial)
